Department of HIV, World Health Organization, Geneva, Switzerland.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
J Int AIDS Soc. 2019 Nov;22(11):e25415. doi: 10.1002/jia2.25415.
INTRODUCTION: Guidelines for antiretroviral therapy recommend enhanced adherence counselling be provided to individuals with an initial elevated viral load before making a decision whether to switch antiretroviral regimen. We undertook this systematic review to estimate the proportion of patients with an initial elevated viral load who resuppress following enhanced adherence counselling. METHODS: Two databases and two conference abstract sites were searched from January 2012 to October 2019 for studies reporting the number of patients with an elevated viral load whose viral load was undetectable when subsequently assessed. Data were pooled using random effects meta-analysis. RESULTS: Fifty-eight studies reported outcomes of 45,720 viraemic patients, mostly from Africa (48 studies), and among patients on first-line antiretroviral therapy (43 studies). Almost half (46.1%, 95% CI 42.6% to 49.5%) of patients with an initial elevated viral load resuppressed following an enhanced adherence intervention. Of those on first-line ART with confirmed virological failure (6280 patients, 21 studies), only 53.4% (40.1% to 66.8%) were appropriately switched to a different regimen. Resuppression was higher among studies that provided details of adherence support. The proportion resuppressing was lower among children (31.2%, 21.1% to 41.3%) and adolescents (40.4%, 15.7% to 65.2%) compared to adults (50.4%, 42.6% to 58.3%). No important differences were observed by date of study publication, gender, viral failure threshold, publication status, time between viral loads or treatment regimen. Information on resistance testing among people with an elevated viral load was inconsistently reported. CONCLUSIONS: The findings of this review suggest that in settings with limited resources, current guideline recommendations to provide enhanced adherence counselling can result in resuppression of a substantial number of these patients, avoiding unnecessary drug regimen changes. Appropriate action on viral load results is limited across a range of settings, highlighting the importance of viral load cascade analyses to identify gaps and focus quality improvement to ensure that action is taken on the results of viral load testing.
简介:抗逆转录病毒治疗指南建议,在决定是否更换抗逆转录病毒方案之前,应对初始病毒载量升高的个体提供强化依从性咨询。我们进行了这项系统评价,以估计初始病毒载量升高的患者在接受强化依从性咨询后病毒载量得到抑制的比例。
方法:从 2012 年 1 月至 2019 年 10 月,我们在两个数据库和两个会议摘要网站上搜索了报告初始病毒载量升高的患者数量的研究,这些患者的病毒载量在随后的评估中不可检测。使用随机效应荟萃分析对数据进行了汇总。
结果:58 项研究报告了 45720 名病毒血症患者的结局,这些研究大多来自非洲(48 项研究),并且是在一线抗逆转录病毒治疗中(43 项研究)。初始病毒载量升高的患者中,有近一半(46.1%,95%CI 42.6%至 49.5%)在接受强化依从性干预后病毒载量得到抑制。在有明确病毒学失败的一线 ART 患者(6280 名患者,21 项研究)中,只有 53.4%(40.1%至 66.8%)被适当转换为不同的方案。提供详细的依从性支持的研究中,病毒载量抑制的比例更高。与成年人(50.4%,42.6%至 58.3%)相比,儿童(31.2%,21.1%至 41.3%)和青少年(40.4%,15.7%至 65.2%)病毒载量抑制的比例较低。研究发表日期、性别、病毒失败阈值、发表状态、病毒载量检测之间的时间、治疗方案等因素均未观察到重要差异。关于病毒载量升高患者的耐药检测信息报告不一致。
结论:本综述结果表明,在资源有限的环境中,目前的指南建议提供强化依从性咨询,可以使大量患者的病毒载量得到抑制,避免不必要的药物方案改变。在一系列环境中,对病毒载量结果的适当处理受到限制,突出了病毒载量级联分析的重要性,以发现差距并集中质量改进,以确保对病毒载量检测结果采取行动。
J Acquir Immune Defic Syndr. 2013-9-1
J Epidemiol Glob Health. 2024-9
BMC Infect Dis. 2019-1-3
J Acquir Immune Defic Syndr. 2018-3-1